The ELISA evaluation of the adipogenesis and osteogenesis status revealed significantly reduced levels of secreted FABP4 and osteocalcin biomarkers in the BMP of newly-diagnosed AML patients compared to HDs (FABP4: 572.8 ± 364.27 pg/ml and 279.7 ± 156.4 pg/ml, respectively; p = 0.039; osteocalcin: 0.00251 ± 0.000832 pg/ml and 0.00141 ± 0.001128 pg/ml, respectively; p = 0.03) (Fig. 1A, B). This evidence concerns the gene FABP4 and acute myeloid leukemia.